CCP
KERX

Clough Capital Partners’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Clough Capital Partners’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-751,101
Closed -$5.33M – 160
2017
Q3 		$5.33M Buy
751,101
+488,800
+186% +$3.51M 0.36% 68
2017
Q2 		$1.9M Buy
262,301
+155,601
+146% +$972K 0.13% 88
2017
Q1 		$657K Buy
106,700
+28,100
+36% +$154K 0.04% 115
2016
Q4 		$461K Buy
78,600
+45,000
+134% +$246K 0.03% 147
2016
Q3 		$178K Sell
33,600
-846,300
-96% -$4.56M 0.01% 170
2016
Q2 		$5.83M Buy
879,900
+9,700
+1% +$54.2K 0.31% 99
2016
Q1 		$4.06M Sell
870,200
-832,900
-49% -$3.32M 0.19% 116
2015
Q4 		$8.6M Buy
1,703,100
+70,800
+4% +$336K 0.4% 79
2015
Q3 		$5.75M Buy
+1,632,300
New +$10.9M 0.25% 90

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Clough Capital Partners's KERX Position: Q4 2017 in Review

Clough Capital Partners sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 751,101 shares — an estimated $5.33M sold.

Clough Capital Partners first reported a position in KERX in Q3 2015 and held it in 9 quarters. The position peaked at $8.6M in Q4 2015. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Clough Capital Partners reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Clough Capital Partners sold 751,101 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $5.33M.
  • Clough Capital Partners first reported a position in Keryx Biopharmaceuticals Inc in Q3 2015 and held it in 9 quarters.
  • Clough Capital Partners's Keryx Biopharmaceuticals Inc position peaked at $8.6M in Q4 2015.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Clough Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.